Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy

Kim, Hyo Song; Kim, Won Seog; Park, Se Hoon; Jung, Chul Won; Choi, Han Yong; Lee, Hyun Moo; Jeon, Seong Soo; Ha, Hongil; Hwang, In Gyu; Lee, Seungkoo; Lim, Ho Yeong

doi:10.1016/j.urolonc.2008.08.002

Cited by 16 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After carefully review of each of the 50 studies, certain studies were excluded for the following rationale: six studies evaluated CAIX status by enzyme-linked immunosorbent assay (ELISA) [23], [24], [25], [26], [27], [28]; five studies evaluated CAIX status by real-time-PCR [29], [30], [31], [32], [33]; one study was on the topic of a single nucleotide polymorphism in the CAIX gene [34]; fourteen studies did not report survival outcome on CAIX expression or survival outcome could not be extracted [17], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]; and nine studies contained overlapping data with other studies by the same authors or institutions [48], [49], [50], [51], [52], [53], [54], [55], [56]. Thus, fifteen papers were included in our meta-analysis to evaluate the relationship between CAIX expression and prognosis in patients with renal cell carcinoma [16], [18], [19], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68]. The selection process is shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression in Renal Cell Carcinoma: A Meta-Analysis of the Literature

Zhao

Liao

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundCarbonic anhydrase IX (CAIX) protein has been correlated with progression and survival in patients with renal cell carcinoma (RCC). The prognostic value of CAIX in RCC however, remains inconclusive according to published works. This study aimed to analyze CAIX as a biological marker to predict RCC patient prognosis.MethodsA literature search of the PubMed and Web of Knowledge databases was performed to retrieve original studies from their inception to December of 2013. Fifteen studies, collectively including a total of 2611 patients with renal cell carcinoma, were carefully reviewed. Standard meta-analysis methods were applied to evaluate the prognostic impact of CAIX expression on patient prognosis. The hazard ratio (HR) and its 95% confidence interval (CI) were recorded for the relationship between CAIX expression and survival, and the data were analyzed using Review Manager 5.2 software and Stata software 11.0.ResultsIn patients with RCC, low CAIX expression was associated with poor disease-specific survival (HR = 1.89, 95% CI: 1.20–2.98, P = 0.006), unfavorable progression-free survival (HR = 2.62, 95% CI: 1.14–6.05, P = 0.02) and worse overall survival (HR = 2.03, 95% CI: 1.28–3.21, P = 0.002). Furthermore, low CAIX expression was significantly associated with the presence of lymph node metastases (odds ratio (OR) = 0.31, 95% CI = 0.15–0.62, P = 0.0009) and distant metastases (OR = 0.66, 95% CI = 0.46–0.96, P = 0.03) and predicted a higher tumor grade (OR = 0.41, 95% CI = 0.31–0.54, P<0.00001).ConclusionsLow CAIX expression most likely indicates poor prognosis in RCC patients. Moreover, low CAIX expression was significantly associated with unfavorable clinicopathological factors. To strengthen our findings, further well-designed prospective studies should be conducted to investigate the role of CAIX expression in RCC.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression in Renal Cell Carcinoma: A Meta-Analysis of the Literature

Zhao

Liao

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…remaining 42 articles were reviewed, and of these 23 were excluded, the reasons for which are shown in Figure 1. Thus, 19 studies were included in the quantitative synthesis [10,[19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. Five of these studies [20,22,25,33,36] did not provide data (HR or Kaplan-Meier curve) to calculate the HR for OS, PFS, or DSS, and therefore could not be included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Multivariate analysis indicated that CD147+/VEGF+ and CD147−/VEGF− co-expression were independent prognostic indicators for RCC [22]. A study performed in 2010 by Kim et al [20] examined RCC tissue for carbonic anhydrase IX, cyclooxygenase-2 (COX-2), and VEGF expression in tissue from 62 patients with RCC, and found that high carbonic anhydrase and COX-2 staining were associated with a better response to cytokine therapy, whereas VEGF expression did not provide prognostic information.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis

Shen

Liu

et al. 2017

CIM

View full text Add to dashboard Cite

Objective: Vascular endothelial growth factor (VEGF) serum level or tumor expression may be prognostic in renal cell carcinoma (RCC). The purpose of this meta-analysis was to examine the prognostic value of serum VEGF level and tumor expression in patients with RCC.Methods: PubMed and EMBASE databases were searched until September 26, 2016. Prospective and retrospective studies of RCC patients that had VEGF levels measured were included. Outcome measures were overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS).Results: A total of 14 studies were included in the meta-analysis. In patients with RCC, elevated serum VEGF level was not associated with OS (pooled hazard ratio [HR] = 1.16; 95% confidence interval [CI]: 0.52 to 2.60; p = 0.716), but was associated with poor DSS (pooled HR = 4.22; 95% CI: 2.02 to 8.79; p < 0.001) and PFS (pooled HR = 1.50; 95% CI: 1.22 to 1.85; p < 0.001). Removal of one study, however, resulted in elevated serum level being associated with poorer OS. Tumor VEGF expression was not associated with OS (pooled HR = 1.48; 95% CI: 0.74 to 2.95; p = 0.263), but was associated with worse DSS (pooled HR = 1.83; 95% CI: 1.24 to 2.71; p = 0.003). Conclusion:In patients with RCC, elevated serum VEGF level is associated with worse OS, DSS, and PFS, while tumor expression is only associated with worse DSS. The number of studies, however, was limited and the results should be interpreted with caution.

show abstract

“…De la controversia respecto a su valor pronóstico se puede inducir que ACIX pueda tener más valor predictivo de respuesta al tratamiento que valor pronóstico en sí misma. Ello está claramente validado en tumores mestastáticos tratados con IL-2 [11][12][13] . En relación con las terapias diana, la expresión de ACIX se ha validado como factor predictivo de respuesta a sorafenib 16 y no se ha relacionado con la respuesta a temsirolimus, donde una expresión alta de phospho-Akt o phospo-S6, moléculas upstream y downstream de la ruta de señalización celular gobernada por mTOR, sí que se …”

Section: Discussionunclassified

Expresión inmunohistoquímica de la densidad microvascular y de la anhidrasa carbónica IX en carcinoma renal: Relación con el tipo histológico y con la progresión tumoral

et al. 2011

View full text Add to dashboard Cite

PALABRAS CLAVEAnhidrasa carbónica IX; Carcinoma renal; Inmunohistoquímica; Densidad microvascular; Predicción; Pronóstico ResumenObjetivos: relacionar la expresión inmunohistoquímica (IHQ) de la densidad microvascular (DMV) y de la anhidrasa carbónica IX (ACIX) con los tipos histológicos de carcinoma renal (CR) y con su progresión. Material y métodos: se estudiaron 93 pacientes operados por CR entre 1990-2008. Anticuerpos: CD31 (1: 40, Dako) y CD34 (1: 50, Dako) para DMV y ACIX (1: 100, Santa Cruz). ACIX se valoró semicuantitativamente; intensamente positivos (>85%), débilmente positivos (10-85%) y negativos (< 10%), independientemente de la intensidad de la tinción. La DMV se valoró independientemente con anti-CD31 y anti-CD34. Campo de bajo aumento (x100) con mayor densidad de vasos teñidos; se contabilizó el número de vasos en un campo fotográfico de 0,53 mm 2 . Resultados expresados como número máximo de vasos/ mm 2 de tejido tumoral. Resultados: mediana seguimiento; 40 meses (1-160). No encontramos diferencias IHQ para ninguno de los 3 marcadores entre tumores que progresan (49) y no progresan (44). La expresión de ACIX estaba relacionada con la DMV (p < 0,0001). La DMV se relacionó inversamente con el tamaño tumoral y con el grado de Fuhrman de forma significativa. Así mismo, fue significativamente mayor en los CR de células claras, tanto medida con CD31 (p = 0,001) como con CD34 (p = 0,003) frente al resto de subtipos histológicos. Conclusiones: la DMV y la expresión de ACIX no se relacionan con la progresión, pero sí con el tipo tumoral. Ello y su coexpresividad permitiría usar la expresión de ACIX como medida orientativa rápida y fácil para medir DMV y su posible relación con la respuesta a antiangiogénicos.

show abstract

Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy

Cited by 16 publications

References 23 publications

Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression in Renal Cell Carcinoma: A Meta-Analysis of the Literature

Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression in Renal Cell Carcinoma: A Meta-Analysis of the Literature

The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis

Expresión inmunohistoquímica de la densidad microvascular y de la anhidrasa carbónica IX en carcinoma renal: Relación con el tipo histológico y con la progresión tumoral

Contact Info

Product

Resources

About